Selected-GenAtlas references	SOURCE	GeneCards	NCBI Gene	Swiss-Prot	Orphanet	Ensembl
	HGNC	UniGene	Nucleotide	OMIM		UCSC

Home Page

FLASH GENE

Symbol

EGFR

contributors: mct/pgu - updated : 05-11-2019

HGNC name	epidermal growth factor receptor
HGNC id	3236

FLASH GENE DNA RNA EXPRESSION PROTEIN DISORDER ANIMAL & CELL MODELS

ASSOCIATED DISORDERS

corresponding disease(s)

Other morbid association(s)

Type Gene Modification Chromosome rearrangement Protein expression Protein Function tumoral   amplification     in prostate carcinoma, brain astrocytomas and gliomas (tandemly duplicated tumoral   deletion     in brain glioblastoma tumoral somatic mutation       in malignant oral keratinocytes and in non-small cell lung cancer of non-smokers tumoral   amplification     short alleles of polymorphic CA repeat located at a 5-regulatory sequence in the intron 1 associated with increased expression in osteosarcoma tumoral   amplification     frequent alterations in primary melanomas and associated with bad prognosis tumoral     --over   correlated with poor prognosis in Glioblastoma multiforme patients

Susceptibility

to non-small cell lung cancer

Variant & Polymorphism other	germline mutation T790M in non-small cell lung cancer, mutation drug resistance, stimulating DNA synthesis and cytoskeletal rearrangement in breast cancer (MCF-7) and prostate cancer (LNCaP) cells

Candidate gene
Marker
Therapy target
	System Type Disorder Pubmed cancer     important target of cancer drug design (inhibition of EGFR signaling in cancer cells induces NOTCH1 gene expression through TP53) cancer lung   lung adenocarcinomas with activating mutations in EGFR often respond to treatment with EGFR tyrosine kinase inhibitors (TKIs), but the magnitude of tumour regression is variable and transient cancer head and neck   dual blockade of MET and EGFR may be a promising clinical therapeutic strategy for treating HNSCC dermatology skin   is a potential therapeutic target for pemphigus miscelleaneous urinary   targeting HDAC6 to downregulate EGFR activity may provide a potential therapeutic approach to treat polycystic kidney disease cancer reproductive prostate blockade of EGFR signaling could be more effective in preventing and retarding PCa progression toward metastasis miscelleaneous urinary chronic kidney disease most promising targets for future therapeutic development in Polycystic kidney disease (PKD)are those that target upstream signaling events at cell membranes, such as the vasopressin-2 receptor (AVPR2), EGFR/ERBB2

ANIMAL & CELL MODELS